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Positron emission tomography (PET) using 18fluoro-2-deoxyglucose (FDG) has become a standard clinical tool for
staging and response assessment in aggressive lymphomas. The use of PET scans in clinical trials is still under
exploration, however. In this review, we examine current data regarding PET in DLBCL, and its potential applicability
to development of a surrogate endpoint to expedite clinical trial conduct. Interim PET scanning in DLBCL shows
mixed results, with qualitative assessment variably associated with outcome. Addition of quantitative assessment
might improve predictive power of interim scans. Data from multiple retrospective studies support that PET-defined
response at end of treatment correlates with outcome in DLBCL. Optimal technical criteria for standardization of
acquisition and criteria for interpretation of scans require further study. Prospective studies to define the correlation
of PET-defined response and time-dependent outcomes such as progression free survival (PFS) and overall survival (OS),
critical for development of PET as a surrogate endpoint for clinical trials, are ongoing. In conclusion, evolving data
regarding utility of PET in predictcing outcome of patients with DLBCL show promise to support the use of PET
as a surrogate endpoint in clinical trials of DLBCL in the future.
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The noninvasive, three-dimensional, functional imaging
technique known as positron emission tomography (PET)
has become an increasingly powerful tool in clinical on-
cology. Throughout the past decade, a wealth of data have
been gathered regarding the role of PET in lymphoma,
and PET has taken a prominent role in clinical care of pa-
tients with lymphoma. An ongoing challenge is to put
these data to use in clinical trials, whether as a surrogate
endpoint or as an aid in early drug development. PET im-
ages show snapshots of biochemical processes in vivo by
relying on injected compounds labeled with positron emit-
ting radionuclei [1]. 18Fluoro-2-deoxyglucose (18F-FDG or
FDG), a glucose analog, is the most commonly used PET
tracer in oncology, and references to PET throughout this
article refer to FDG-PET. After injection, FDG is taken up
by cells and subsequently phosphorylated in the same
process as glucose. The phosphorylated product, however,* Correspondence: elstrom.rebecca@gene.com
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article, unless otherwise stated.is not further metabolized and remains trapped in the cells
for extended periods of time [2]. This accumulation of
FDG is detected by PET, and provides visualization of
glucose consumption by different cells. The fact that
metabolism in cancer cells is fundamentally altered
was first described by Warburg in the 1920s, and the
mechanisms by which this deranged metabolism oc-
curs has been the subject of extensive investigation,
which has illuminated a variety of oncogenic pathways
that contribute to the effect [3].
This fundamental requirement for cancerous cells to
upregulate their glucose metabolism allows PET to be a
useful tool in oncology. Cancerous cells show increased
amounts of the membrane glucose transporters, GLUT-1
and GLUT-3, increased hexokinase, and overall aug-
mented glucose metabolism [3,4], making FDG an optimal
tracer for measuring viability of malignant cells. When
combined with the anatomical imaging tool computed
tomography (CT), PET/CT scans give more accurate
images that can discriminate between physiological and
pathological FDG uptake, as well as between necroticd Central Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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bined PET/CT scans underlies the utility of PET for the
staging, monitoring, and restaging of many cancers in-
cluding non-small cell lung, colorectal, esophageal, and
head and neck cancers, melanoma, as well as lymphoma
[5]. The role of PET scanning using FDG in lymphoma,
particularly regarding the use of PET in optimizing con-
duct and interpretation of clinical trials for DLBCL, will
be the focus of the remainder of this review.Review
Biological and technical parameters- what influences the
final scan?
Both biological and technical factors can influence the
final PET image (Table 1). Many of the biological factors
can vary from patient to patient, making them difficult
to control. These biological factors, such as amount of
and location of brown fat, post-chemotherapy thymic re-
bound, the use of granulocyte macrophage-colony stimu-
lating factor, inflammation, and infection, can have a
confounding effect on PET images. These factors are often
falsely identified as active disease on PET images because
they cause FDG uptake in regions not compatible with
normal physiological FDG uptake [6]. A patient with
lymphoma, for example, who has brown fat around the
cervical lymph node region, could be incorrectly iden-
tified as having active disease because the brown fat
also has a high level of FDG uptake.
Technical components of the scanning technique that
influence the final image include factors such as FDG
dose, image reconstruction, and spatial resolution of the
scanner [7]. The procedures guiding these components
can vary across scanners and institutes. With the grow-
ing use of PET in lymphoma and other cancers, and as a
prerequisite to establishing PET as a possible surrogate
endpoint in clinical trials, there is a need to standardizeTable 1 Biological and technical factors affecting PET
images
Biological: Technical:




•Brown Fat • bed overlap
•Inflammatory cause • FDG dose
•Hyperplasia in the bone marrow post
granulocyte colony-stimulating factor
Image reconstruction and
spatial resolution of scanner
•Patients motion/breathing Timing of PET scan after FDG
administration
•Patient comfort ROI strategy and normalization
calculation
•Blood glucose level Use of contrast agents during CTpatient preparation and scan acquisition, as variability in
these areas can impact the quality and reproducibility of
scan interpretation across centers. This variability could
impact the results within a multi-center study, as well as
make the comparison of results across studies difficult.
Several standardized protocols have been developed for
use in clinical trials. In an attempt to standardize
whole-body PET for multi-center clinical trials in the
Netherlands for example, the Dutch Society of Nuclear
Medicine implemented a protocol that included pa-
tient preparation, administration procedure, FDG dos-
ing, resolution matching, data analysis, standardized
uptake value (SUV) normalization, and quality control
approaches [7]. This protocol was designed in an attempt
to minimize errors in obtaining SUV measurements so
that these SUV results could be interchangeable across
centers [8].
A UK-based group published another example of a
standardized PET protocol with the goal of ensuring the
acquisition of quality scans in UK trials. This group
established a clinical trials network (CTN) that PET cen-
ters could join by adhering to quality control and the
specified acquisition procedure. A “core laboratory” was
set up for quality control procedures and scan interpret-
ation in order to obtain uniformity and high-quality re-
sults across the CTN. The CTN has been used in three
multicenter trials examining the utility of PET in Hodg-
kin lymphoma (HL), and thus far has been shown to be
an effective method of ensuring compliance across PET
centers [9].
A Japan-based multicenter trial evaluating the utility
of interim PET scanning in DLBCL patients included
optimization of the scan acquisition protocol and image
reconstruction parameters. The study group implemented
quality control measures in order to determine the opti-
mal parameters for each PET scanner in the trial. They
also established a trial-specific core laboratory to evaluate
the effectiveness of these measures across the centers, and
the standardization method was shown to be successful in
obtaining quality images [10].
The protocol standardization exemplified by the Dutch,
UK, and Japanese study groups is a model that other
multi-center studies can follow. In the United States, there
have also been published protocols to standardize patient
preparation and scan acquisition. The Cancer Imaging
Program of the National Cancer Institute developed a
PET standardization protocol in 2006 for use in NCI trials.
The NCI recommendations cover patient preparation,
methods of scan interpretation, quality assurance, image
acquisition and reconstruction guidelines, as well as other
technical parameters [11]. These recommendations of-
fered a starting point for the standardization of PET
methodology for the use of FDG-PET as a biomarker
for treatment response in clinical trials [12]. Around
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the purpose of assisting physicians in utilizing com-
bined PET/CT for oncologic imaging [13]. One chal-
lenge to scan standardization in countries where PET
scans are more widely available due to the use of mo-
bile PET scanners, such as in the US, is that the vari-
ability across this type of scanner and the impact of
their constantly changing environments increase the
challenges in maintaining consistent quality control.
Despite this difficulty, standardization of patient prep-
aration, scan acquisition, and quality control are be-
coming components of many current PET studies,
improving quality and contributing to more reprodu-
cible PET results.
PET in lymphoma- when do we use it?
Oncologists increasingly use PET in the routine staging
of many types of lymphoma to clarify the extent of dis-
ease involvement and to help direct treatment options
[14]. With few exceptions, such as small lymphocytic
lymphoma (SLL), the vast majority of malignant lymph-
omas, including both aggressive and indolent subtypes,
are reliably FDG-avid, and therefore detectable on PET
scanning [15-17]. Although a thorough discussion of
lymphoma staging using PET is outside the scope of this
review, detection of bone marrow involvement merits
mention, given its relevance to clinical trial procedures
and assessments. The probability of involvement of bone
marrow in lymphoma varies by histology, and can have
an impact on both prognosis and management. Assess-
ment of lymphoma involvement of bone marrow is histor-
ically done by iliac crest aspirate and biopsy, a procedure
that is often uncomfortable for patients, and provides only
local assessment of potential involvement. While the util-
ity of CT scanning is limited to detection of destructive
bone lesions, PET is able to detect involvement of bone or
bone marrow in many cases [16-18]. Several studies have
addressed the question of whether PET and bone marrow
biopsy both contribute relevant staging information. It is
clear that PET scanning detects focal lesions that cannot
be identified by iliac crest biopsy. However, the added
information provided by bone marrow biopsy in the
setting of PET scan has been a subject of controversy.
This controversy could be due in part to inclusion of
differing histologic subtypes of lymphoma; notably, recent
studies including only DLBCL and using modern PET
technology continue to show divergent results regarding
additional clinical and prognostic information obtained
from BMB [19-22].
Since the publication of the 2007 Revised Response
Criteria for Malignant Lymphoma [23] (subsequently
updated as the Lugano Classification [24]), end of
treatment response assessment for FDG-avid lymph-
omas routinely incorporates PET results. PET has alsobeen explored in assessment of early or interim response
to treatment and to predict post-treatment prognosis [25].
Interim PET imaging refers to imaging performed dur-
ing a planned course of therapy, prior to completion,
with the goal of predicting the outcome of that course of
treatment. If interim imaging can predict early in the
course of therapy that a specific treatment will not be ef-
ficacious, therapy can potentially be altered prior to
completion of the entire course. This could spare pa-
tients toxicity of non-efficacious therapy, and allow revi-
sion to a potentially more effective regimen in patients who
are destined to respond poorly to the initial treatment.
Interim PET imaging has been explored most exten-
sively in Hodgkin Lymphoma (HL), but has also been
examined in DLBCL and FL. In DLBCL, although many
patients are cured, those patients who do not respond to
or who relapse after standard first line therapy have poor
survival [26]. Therefore, if interim PET could predict re-
sponse to treatment or survival, patients who are
responding poorly to therapy might be identified early in
the treatment course. If a patient were found to have a
poor chance of achieving good results from the current
treatment regimen based on interim PET, the therapy
could then potentially be altered in hopes of achieving a
better outcome. A caveat to this use of PET is that the
interpretation of interim PET should have low rate of
false positives, in order to avoid altering a patient’s treat-
ment from a truly effective regimen.
Although end of treatment PET scan results are rou-
tinely used for response assessment in clinical practice,
PET scans have not yet been systematically incorporated
into clinical trial assessments. The time frame for end of
treatment PET imaging is 6-8 weeks after the comple-
tion of therapy [23], and the median PFS for frontline
DLBCL patients is approximately 5 years [27]. If the end
of treatment PET result could be systematically corre-
lated with PFS or overall survival, then PET could poten-
tially be used as a surrogate endpoint in clinical trials.
This would effectively shorten clinical trials, thereby
making novel treatment for patients available sooner.
PET interpretation criteria
There has been much debate about the appropriate
method of interpreting PET scans at both the interim
and end of treatment time point. As mentioned earlier,
the Revised Response Criteria for Malignant Lymphoma
incorporates PET scans performed at the end of treat-
ment as a major determinant of response. The criteria
that were developed for interpreting end of treatment
PET scans for malignant lymphomas are known as the
International Harmonization Project, or IHP, criteria.
These criteria depend on a visual comparison of FDG
uptake in the large residual lesions to that of the medias-
tinal blood pool (MBP), and of FDG uptake in smaller
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rounding background [28] (Table 2). Because of their in-
corporation into the 2007 standard Response Criteria
[23], this method of evaluation is commonly used in
assessment of end of treatment PET scans.
A second criterion that has been used to interpret
PET scans is a five-point visual scale known as the Deau-
ville criteria (Table 2). The Deauville criteria, also known
as the London criteria, were first used for interpretation
of interim PET scans in HL. These criteria were shown
to provide a robust and reproducible method of inter-
preting interim scans in HL, and are currently the refer-
ence standard in a study designed to validate the utility
of interim PET in HL [9]. In 2009, at the annual inter-
national workshop for interim PET in DLBCL and HL
held in Deauville, France, this five-point visual scale was
proposed for use in DLBCL in addition to HL [29], and
has recently been incorporated into the updated stand-
ard response criteria for lymphoma (The Lugano Classi-
fication) [24]. The Deauville criteria depend on a visual
comparison of FDG uptake in regions of interest to that
of the liver, which generally shows higher FDG uptake
than the MBP. This difference in reference background
organ represents a key differentiator between the Deauville
and the IHP criteria, with the Deauville having a higher
tolerance of residual uptake than the IHP.
A third approach to scan interpretation uses changes
in quantitative measures of FDG uptake from baseline to
interim or end of treatment scans to identify responders
and non-responders to therapy. Standardized uptake
value (SUV) is a semi-quantitative measurement of in-
tensity of FDG uptake in a given area of a scan. One
variable that is under investigation as a response tool is
the change in maximum standardized uptake value
(ΔSUVmax). Other quantitative variables under explor-
ation include ΔSUVmean, total lesion glycolysis, and
metabolic tumor volume (Table 3). These quantitative ap-
proaches to interpreting scans have shown promise in
minimizing reader bias and improving reproducibility;Table 2 Criteria for PET interpretation
International Harmonization Project (IHP) criteria (adapted
from Juweid 2007) [28]:
Definition of a positive scan:
Focal or diffuse FDG uptake above background in a location incompatible w
normal physiology
Exceptions:
1.) Mild FDG uptake at the side of moderate to large residual masses with lo
intensity visually compared to the mediastinal blood pool structures.
2.) FDG uptake in residual hepatic or splenic lesions should be compared to
uptake in surrounding normal liver or spleenhowever, these quantitative analyses also require more
stringent scan acquisition protocols.
Interim PET in DLBCL
Interest in the use of interim PET in DLBCL stems in
part from observations that suggest excellent prognostic
power of interim PET in HL. A number of small studies
in the last decade suggested that PET scan results ob-
tained after one to 3 cycles of chemotherapy correlated
well with outcome in both HL and DLBCL [33-35]. In
2007, a study evaluating interim PET results in patients
with HL demonstrated that interim PET was a powerful
predictor of outcome in patients with advanced HL [36].
Patients who were identified as having a positive PET
scan at interim showed consistently dismal outcome to
standard therapy, whereas those with negative scans
showed excellent rates of cure, demonstrating high posi-
tive and negative predictive power in this patient popula-
tion. The Response Adapted Treatment in Hodgkin
Lymphoma (RATHL) trial is an ongoing follow up study
that is designed to further establish the prognostic cap-
abilities of interim PET in HL [9]. Both the strong data
in support for using interim PET scanning in HL and the
establishment of a reproducible, standardized method of
interpretation in this indication have set the bar for in-
terim PET in DLBCL.
In contrast to HL, although early data in support of
the use of interim PET scanning in DLBCL were promis-
ing, more recent studies, conducted in the era of stand-
ard rituximab use in NHL, have shown poor predictive
power of interim PET in DLBCL. One potential reason
for this discrepancy is based on the ability of rituximab
to recruit inflammatory cells to sites of disease. These
inflammatory cells have a high rate of glucose metabol-
ism and therefore are FDG-avid, resulting in false posi-
tive results on PET [37].
Several studies have examined the utility of interim PET
in DLBCL in the rituximab era, with conflicting results.
Although some have shown good correlation of interimDeauville criteria (Meignan 2009) [29]:
1. No uptake
ith 2. Uptake ≤ mediastinum
3. Uptake > mediastinum but ≤ liver
wer 4. Uptake moderately > liver uptake, at any site
the 5. Markedly increased uptake at any site and new sites of disease.
A positive scan is usually interpreted as one showing areas of
residual uptake with a score of ≥4, though criteria may vary
Table 3 Definitions of quantitative FDG measurements
Measure Definition Notes
Standardized Uptake Value (SUV) [30] Relative tissue FDG uptake adjusted for amount injected
and body weight
Variable based on injected tracer, time of
uptake
SUVmax [30] Hottest pixel in defined region of interest (ROI)
SUVmean [30] Average SUV within a ROI May vary depending on operator definition
of ROI
Metabolic Tumor Volume (MTV) [31,32] Total volume of lesion pixels exceeding a threshold
value
Dependent on definition of ROI
Total Lesion Glycolysis (TLG) [32] Product of MTV and SUVmean
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shown either no correlation or relatively poor positive pre-
dictive power [41-45], limiting the clinical utility of the find-
ings. One of the first to address this issue, by Moskowitz
and colleagues, showed no difference in outcome between
patients with a negative vs. a positive PET after 4 cycles of
R-CHOP chemotherapy. While the generalizability of this
finding was questioned based on a dose-dense chemother-
apy regimen and the fact that all patients underwent a
change in therapy after the PET scan, this study raised the
possibility that DLBCL might be quite different from HL in
terms of utility of interim PET [45].
Other studies have shown a statistical difference in
outcome based on interim PET findings, but the clinical
relevance of the difference has been questioned, particu-
larly with respect to whether the positive predictive
power is strong enough to prompt a change in thera-
peutic approach. For example, a study by Cashen and
colleagues evaluating the prognostic capability of DLBCL
interim PET results interpreted using the IHP criteria
showed that there was indeed a statistically significant
difference in EFS based on interim PET results, with 63%
of patients with a positive PET free of an event at 2 years
vs. 85% of those with a negative interim scan (p = 0.04).
The authors, however, argued that the difference in PFS
was not clinically meaningful, and that the difference in
outcome between the two prognostic groups was not
strong enough to alter treatment based on interim PET
result [43]. Another retrospective study used the Deauville
criteria to interpret interim PET scans, with the goal of de-
termining the predictive value of interim PET for PFS in
DLBCL patients. The results of this study showed only a
weak correlation between interim PET result and PFS,
with 85% of patients with a negative interim scan and 72%
of patients with a positive interim scan progression free at
2 years (p = 0.047). This finding suggests that the two
prognostic groups identified did not have a clinically
meaningful difference in outcome. The rate of false posi-
tive interim PET scans, patients who were identified as
PET positive at interim but then had prolonged remission,
was high in this study [44].The lack of compelling evidence for strong predictive
power of positive interim PET for long term outcome
has prompted some investigators to evaluate a quantita-
tive approach, measuring changes in the semiquantita-
tive SUV [41,46]. A retrospective analysis by Casasnovas
and colleagues evaluated the optimal ΔSUVmax for
DLBCL interim PET scans, and compared the predictive
power of this cutoff to that of interpretation by modified
IHP criteria [47]. The study examined the changes in
maximum SUV from baseline to interim scans taken
after 2 cycles of therapy (PET2) and after four cycles of
therapy (PET4). At both time points, the quantitative
models better predicted PFS than the visual assessments.
The authors retrospectively identified a ΔSUVmax of >70%
at PET4 as the optimal cutoff for distinguishing long term
outcome and the interim PET4 results were more predict-
ive than PET2. However, the best separation of prognostic
groups was identified when combining the PET4 ΔSUVmax
of >70% with the visual assessment . Using this strategy,
the authors showed that 75% of patients with a positive
PET4 and ΔSUVmax of ≤70% relapsed within 8 months,
whereas 2 year PFS was >90% in those patients with either
a negative PET4 or ΔSUVmax at PET4 of >70%. These
results suggest that either a quantitative or a combined
quantitative/visual approach might improve the predict-
ive power of interim PET in DLBCL, although these re-
sults would require prospective validation. A caution
to using the quantitative approach is that SUV tends to
be more sensitive to the patient preparation and scan
acquisition procedures, so relying on this variable
would require more stringent standardization in proto-
cols such as that seen in Dutch, UK, and Japanese
study groups discussed earlier.
The reproducibility of results across readers and cen-
ters is another important consideration in using interim
scanning. Although this standardization has been fairly
effective in HL, it has been more challenging in inter-
pretation of interim PET scans in DLBCL. A study by the
Eastern Cooperative Oncology Group (ECOG) evaluating
PET-based therapeutic interventions also included a sub-
study examining the agreement of scan interpretation
Coughlan and Elstrom Cancer Imaging 2014, 14:34 Page 6 of 9
http://www.cancerimagingjournal.com/content/14/1/34across three readers when using both modified IHP cri-
teria and the Deauville criteria [48]. In this study, agree-
ment between readers was 68% for the modified IHP
criteria (κ statistic =0.445) and 71% (κ = 0.502) for the
Deauville criteria, demonstrating only a moderate level of
agreement in interpretation, even between expert readers.
These results are in contrast to those observed in a large
Phase 3 study in HL, in which scan interpretation using
the Deauville criteria was shown to be reproducible across
centers (κ = 0.79 to 0.85) [9]. This finding emphasizes the
need for a consistent, standardized approach to interpret-
ation of DLBCL interim PET scans.
Overall, the utility of interim PET in DLBCL patients
remains to be validated. The variety of criteria available
for interpretation has made it difficult to compare re-
sults across trials, thus making it difficult to understand
the role interim PET scanning might play in DLBCL. An
approach incorporating quantitative measurements might
be superior to a qualitative approach, but this would
require a standardized scan acquisition protocol to
make results reproducible, and further prospective study
is required to validate this approach.
PET at end of treatment in DLBCL
Currently, response assessment at end of treatment in
clinical practice routinely incorporates PET scanning for
patients with DLBCL. The 1999 International Workshop
Criteria (IWC) for NHL defined responses after treat-
ment, with a designation for complete remission/uncon-
firmed (CRu) to account for the difficulty in assessing
the viability of residual masses with CT alone [49]. In
the following years, a number of studies examined the
value of PET at the conclusion of therapy in lymphoma,
demonstrating that the addition of end of treatment
PET results, interpreted using visual criteria, resulted in
a better correlation of response with long term outcome
when compared to the anatomic assessment alone [50].
A systematic review published by Zijlstra and colleagues
in 2006 demonstrated that, in spite of methodological
variation, the predictive power of PET at end of therapy
for determining outcome in aggressive NHL was very
strong [51], with reported pooled sensitivity of 72% and
specificity of 100%. This prompted an effort to further
standardize the use of PET in lymphoma and to inte-
grate end of treatment PET results into lymphoma response
assessment. An International Harmonization Project (IHP)
developed recommendations for the interpretation of
post-treatment PET scans using visual assessment, and
these recommendations were incorporated into the
2007 Revised Response Criteria for Malignant Lymphoma
[23]. These criteria have been the standard method of
interpreting end of treatment PET scans to assess treat-
ment response. However, these interpretation criteria were
developed using data from patients treated in part beforethe widespread use of rituximab in the standard of care
therapy for DLBCL patients.
In a study published in 2009, Han and colleagues exam-
ined the predictive power of post-treatment PET scans in
aggressive B cell lymphomas treated with rituximab-
containing regimens [52]. In this study, scans were
assessed visually as positive or negative based on a
comparison with the MBP, similar to the IHP criteria.
However, the results showed poor predictive power of
the end of treatment PET result, with positive predict-
ive power of only 19%, and the two groups identified
by positive vs. negative end of treatment PET result
did not show significantly different PFS (p = 0.47). The
authors suggested that the high rate of false positive
scans was due to the use of rituximab in the patient
population. Other studies performed in the rituximab
era that used the IHP criteria to assess DLBCL end of
treatment PET scans did show a statistically significant
difference in outcome between patients identified as
having a negative vs. a positive end of treatment PET
scan, but the positive predictive value of these studies
was variable (30-70%) [43,44]. More recently, Manohar
and colleagues compared three different interpretation
criteria for PET scans performed at end of therapy in
patients with aggressive NHL [53]. The authors inter-
preted a set of end of treatment PET images using the
IHP criteria, the Deauville criteria, and a semi-quantitative
approach that uses an SUVmax cutoff of 3.5 (referred to as
the Gallamini criteria) to determine which criteria best
predicted outcome. The Gallamini and Deauville criteria
were shown to better distinguish outcome between pa-
tients with positive vs. negative scans than the IHP, with
accuracy of 88%, 84%, and 71% respectively. The authors
noted that the main difference between the Gallamini and
Deauville criteria and the IHP was that the IHP criteria
produced a larger number of false positive results. The
authors recommended the Deauville criteria over the
semi-quantitative Gallamini criteria due to their sim-
plicity in interpretation. The results from this study
suggest that minimal residual FDG uptake at end of
treatment is not associated with elevated chance of re-
lapse, and that a higher threshold for determination of
residual FDG uptake may be more predictive of out-
come than that defined by the IHP criteria. Similar
findings were reported by Martelli and colleagues, who
showed that, in patients with primary mediastinal
DLBCL, response assessment at end of treatment using
the Deauville criteria better correlated with outcome
than response assessment using IHP criteria [54].
The recommendation to use Deauville criteria at end
of treatment in place of IHP criteria has been incorpo-
rated into updates of expert recommendations in PET
imaging, such as that from the 4th International Work-
shop on Positron Emission Tomography in Lymphoma
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criteria, the Lugano classification [24], due to its im-
proved reproducibility and correlation with outcome in
DLBCL.
Leveraging PET in clinical trials
The clinical utility of PET scanning in lymphoma has
been demonstrated in terms of both improved staging,
allowing physicians to accurately plan treatment ap-
proach based on disease extent, and response assessment
at end of treatment in order to optimally assess whether
the patient has achieved a complete remission or needs
evaluation for possible residual disease.
The impact of PET scanning on conduct of clinical tri-
als, conversely, has been limited, as evidenced by the fact
that recently-published large, randomized Phase 3 stud-
ies in DLBCL have not systematically reported or even
obtained PET data [56,57]. A major reason for this lack
of impact is the fact that clinical trial endpoints depend
on time-dependent outcome measures, such as overall
survival or its accepted surrogate, progression free sur-
vival. Response rate is not an accepted surrogate for
these time-dependent outcomes, because response, par-
ticularly as defined by conventional CT criteria, is an im-
precise predictor of outcome. While response as defined
by PET at the end of standard first-line therapy is a bet-
ter predictor of PFS than CT-defined response [50], the
power of PET-defined response to predict outcome has
likewise not been established. If such a predictive rela-
tionship could be established, however, the use of PET-
defined response as a surrogate in studies of lymphoma
could provide major advantages in terms of shortening
the timelines of clinical trials, allowing results to be
available faster, with commensurate earlier incorporation
of these results into optimizing care for patients with
DLBCL.
In qualifying a surrogate endpoint, specific criteria should
be met. These include 1) that the endpoint have an ac-
cepted, standardized definition, 2) that there be data from
multiple studies showing strong correlation of the endpoint
with clinical outcome, 3) prospective clinical studies must
validate that the surrogate is truly predictive of clinical out-
come and to what extent, and 4) prospective studies should
determine whether the surrogate endpoint is generalizable
to other patient populations and treatments with alterna-
tive mechanisms [58]. Regarding the potential for use of
PET as a surrogate in DLBCL, criterion number 2 is well
supported. However, additional work is needed to define
the optimal interpretation criteria (criterion number 1).
Trials are currently ongoing attempting to prospectively
validate PET results as a predictor of outcome (criterion 3),
but the fourth point, determination of the utility of PET in
the setting of treatments with differing mechanisms of ac-
tion, will be an ongoing challenge. One could imagine thattherapies targeting signaling pathways that directly interfere
with glucose metabolism, such as PI3K inhibitors, could be
less reliably associated with long term outcome, though
providing an excellent measure of drug targeting.
Conclusions
In summary, PET scanning holds great promise in both
clinical treatment and facilitation of clinical trials on
DLBCL. More work is needed to understand the best in-
terpretation methods and settings for the use of PET
scanning. We eagerly await studies addressing these out-
standing questions.
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